NYSEAMERICAN:XTNT Xtant Medical (XTNT) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free XTNT Stock Alerts $0.92 +0.01 (+1.21%) (As of 12:48 PM ET) Add Compare Share Share Today's Range$0.90▼$0.9450-Day Range N/A52-Week Range$0.60▼$1.45Volume24,544 shsAverage Volume144,542 shsMarket Capitalization$119.80 millionP/E RatioN/ADividend YieldN/APrice Target$1.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort Interest Get Xtant Medical alerts: Email Address Xtant Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside73.9% Upside$1.60 Price TargetShort InterestHealthy0.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 stars 3.5 Analyst's Opinion Consensus RatingXtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXtant Medical has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.62% of the float of Xtant Medical has been sold short.Short Interest Ratio / Days to CoverXtant Medical has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xtant Medical has recently increased by 45.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXtant Medical does not currently pay a dividend.Dividend GrowthXtant Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XTNT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Xtant Medical this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xtant Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.80% of the stock of Xtant Medical is held by insiders.Percentage Held by Institutions69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioXtant Medical has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe only accurate crypto trading system I know …Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.Here's what our expert says you should buy before April 14. About Xtant Medical Stock (NYSEAMERICAN:XTNT)Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.Read More XTNT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XTNT Stock News HeadlinesApril 19, 2024 | americanbankingnews.comXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above Two Hundred Day Moving Average of $0.00April 2, 2024 | finance.yahoo.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2023 Earnings Call TranscriptApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 2, 2024 | finance.yahoo.comQ4 2023 Xtant Medical Holdings Inc Earnings CallApril 1, 2024 | investorplace.comXTNT Stock Earnings: Xtant Medical Hldgs Misses EPS, Beats Revenue for Q4 2023April 1, 2024 | finance.yahoo.comXtant Medical Holdings Inc (XTNT) Reports Record Revenue in 2023, Outpacing Analyst EstimatesApril 1, 2024 | globenewswire.comXtant Medical Announces Record Full Year 2023 Revenue of $91.3 MillionMarch 30, 2024 | finance.yahoo.comXtant Medical Holdings, Inc. (XTNT)April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."March 28, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Trulieve Cannabis (TCNNF), Xtant Medical Holdings (XTNT)March 21, 2024 | globenewswire.comXtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024March 7, 2024 | globenewswire.comXtant Medical Increases Revolving Credit Facility to $17 Million with MidCap FinancialFebruary 26, 2024 | globenewswire.comXtant Medical to Present at the TD Cowen 44th Annual Healthcare ConferenceFebruary 11, 2024 | benzinga.comXtant Medical Hldgs Stock (AMEX:XTNT) Dividends: History, Yield and DatesJanuary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Xtant Medical Holdings (XTNT)December 6, 2023 | msn.comBTIG Initiates Coverage of Xtant Medical Holdings (XTNT) with Buy RecommendationNovember 27, 2023 | msn.comXtant Medical Holdings (XTNT) Price Target Increased by 37.04% to 1.89November 24, 2023 | morningstar.comXtant Medical Holdings Inc XTNTNovember 20, 2023 | msn.comXtant Medical says chief commercial officer Brandt buys 41.7K shares in coNovember 10, 2023 | finance.yahoo.comQ3 2023 Xtant Medical Holdings Inc Earnings CallNovember 9, 2023 | finance.yahoo.comXtant Medical to Participate in Upcoming Investor ConferencesNovember 9, 2023 | msn.comXtant Medical GAAP EPS of $0.07 beats by $0.09, revenue of $25.02M beats by $6.12MNovember 9, 2023 | finance.yahoo.comXtant Medical Announces Record Third Quarter Revenue of $25 MillionNovember 9, 2023 | finance.yahoo.comXtant Medical Holdings Inc (XTNT) Reports Record Q3 Revenue and Raises 2023 GuidanceNovember 2, 2023 | finance.yahoo.comXtant Medical to Issue Third Quarter 2023 Financial Results on November 9, 2023October 24, 2023 | finanznachrichten.deXtant Medical, Inc.: Xtant Medical Announces Acquisition of nanOss Production Operations from RTI SurgicalOctober 23, 2023 | msn.comXtant Medical acquires of nanOss production operations from RTI SurgicalSee More Headlines Receive XTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/24/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolNYSEAMERICAN:XTNT Previous SymbolAMEX:XTNT CUSIPN/A CIK1453593 Webxtantmedical.com Phone(406) 388-0480Fax406-388-1354Employees207Year FoundedN/APrice Target and Rating Average Stock Price Target$1.60 High Stock Price Target$2.00 Low Stock Price Target$1.20 Potential Upside/Downside+76.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$660,000.00 Net Margins0.72% Pretax Margin-1.14% Return on Equity1.56% Return on Assets0.84% Debt Debt-to-Equity Ratio0.34 Current Ratio2.82 Quick Ratio1.22 Sales & Book Value Annual Sales$91.30 million Price / Sales1.30 Cash Flow$0.03 per share Price / Cash Flow28.17 Book Value$0.39 per share Price / Book2.33Miscellaneous Outstanding Shares130,220,000Free Float117,456,000Market Cap$118.37 million OptionableNot Optionable Beta0.22 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Sean E. Browne (Age 58)President, CEO & Director Comp: $1.29MMr. Mark A. Schallenberger (Age 38)Chief Operations Officer Comp: $778.42kMr. Kevin D. Brandt (Age 58)Senior VP & Chief Commercial Officer Comp: $658.03kMr. Scott C. Neils (Age 40)Chief Financial Officer Comp: $517.86kMs. Catherine LundyVice President of Human ResourcesKey CompetitorsMRI InterventionsOTCMKTS:MRICNevroNYSE:NVROGlycoMimeticsNASDAQ:GLYCTruBridgeNASDAQ:TBRGRelmada TherapeuticsNASDAQ:RLMDView All Competitors XTNT Stock Analysis - Frequently Asked Questions Should I buy or sell Xtant Medical stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XTNT shares. View XTNT analyst ratings or view top-rated stocks. What is Xtant Medical's stock price target for 2024? 2 brokerages have issued twelve-month target prices for Xtant Medical's shares. Their XTNT share price targets range from $1.20 to $2.00. On average, they anticipate the company's stock price to reach $1.60 in the next year. This suggests a possible upside of 73.9% from the stock's current price. View analysts price targets for XTNT or view top-rated stocks among Wall Street analysts. Are investors shorting Xtant Medical? Xtant Medical saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 280,600 shares, an increase of 45.8% from the March 15th total of 192,500 shares. Based on an average daily volume of 145,100 shares, the days-to-cover ratio is currently 1.9 days. Approximately 0.6% of the shares of the stock are short sold. View Xtant Medical's Short Interest. When is Xtant Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our XTNT earnings forecast. How were Xtant Medical's earnings last quarter? Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) posted its quarterly earnings results on Monday, April, 1st. The medical device company reported ($0.03) earnings per share for the quarter. The medical device company had revenue of $28.11 million for the quarter. Xtant Medical had a trailing twelve-month return on equity of 1.56% and a net margin of 0.72%. When did Xtant Medical's stock split? Xtant Medical shares reverse split before market open on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What guidance has Xtant Medical issued on next quarter's earnings? Xtant Medical updated its FY 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $112.0 million-$116.0 million, compared to the consensus revenue estimate of $115.9 million. What other stocks do shareholders of Xtant Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xtant Medical investors own include Aurinia Pharmaceuticals (AUPH), LadRx (CYTR), Heat Biologics (HTBX), Neovasc (NVCN), Rexahn Pharmaceuticals (REXN), Biopharmx (BPMX), Adamis Pharmaceuticals (ADMP), Lipocine (LPCN) and Synergy Pharmaceuticals (SGYP). How do I buy shares of Xtant Medical? Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:XTNT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xtant Medical Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
